Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Breast 2Thoracic 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Breast Neoplasms 5Brain Neoplasms 5Glioblastoma 3Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1

Interventions

Therapeutics 4Flow Cytometry 4Filgrastim 4Docetaxel 4Peripheral Blood Stem Cell Transplantation 3Cyclophosphamide 3sargramostim 2liposomal amphotericin B 2Radiotherapy 2Psychiatric Rehabilitation 2Polymerase Chain Reaction 2Paclitaxel 2Ondansetron 2Methylprednisolone 2Itraconazole 2Irinotecan 2Immunologic Techniques 2Dexamethasone 2Caspofungin 2Calcium Dobesilate 2Aprepitant 2Amplified Fragment Length Polymorphism Analysis 2Amifostine 2Alemtuzumab 2thymoglobulin 1temsirolimus 1tanespimycin 1sacituzumab govitecan 1oblimersen 1etoposide phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Ovarian Epithelial × sacituzumab govitecan × CNS × Clear all
NCT01631552 2021-08-12

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Gilead Sciences

Phase 1/2 Completed
515 enrolled 28 charts 1 FDA
BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡